Share this article
Share this article
SAN DIEGO, Feb. 24, 2021 /PRNewswire/ Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme or the Company ), a leader in converting IV biologics to subcutaneous delivery, today announced the pricing of $700 million aggregate principal amount of its convertible senior notes due 2027 (the Convertible Notes ). The Convertible Notes are being offered in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the Securities Act ). The Company granted an option to the initial purchasers to purchase up to an additional $105 million aggregate principal amount of Convertible Notes.
The Convertible Notes will be senior, unsecured, obligations of the Company, will pay interest semi-annually in arrears at an annual rate of 0.25% and under certain circumstances, will be convertible into cash and, if applicable, shares of the Company s common stock, at the Company s election. The Conv
Share this article
Share this article
SAN DIEGO, Feb. 23, 2021 /PRNewswire/ Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme or the Company ), a leader in converting IV biologics to subcutaneous delivery, today announced that it intends to offer, subject to market conditions and other factors, $500 million aggregate principal amount of convertible senior notes due 2027 (the Convertible Notes ). The Convertible Notes are to be offered and sold to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the Securities Act ). The Company also expects to grant a 30-day option to the initial purchasers to purchase up to an additional $75 million aggregate principal amount of Convertible Notes.